$PA8 #Paion AG Paion - Positive prospects with strategic uncertainties: By 5 July 2020, the FDA is due to announce its decision on remimazolam (ByFavo) for procedural sedation (PS). In Japan, Remimazolam (Anerem) was approved in January… https://t.co/TTCXOtG9Ul #equity #stocks https://t.co/wj7ir1p3Sg